Article Details

AstraZeneca's rare disease group Alexion targets amyloidosis in deal worth potential $760m ...

Retrieved on: 2022-01-07 13:12:35

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca's rare disease group Alexion targets amyloidosis in deal worth potential $760m .... View article details on hiswai:

Excerpt

Alexion, AstraZeneca's rare disease group, will $30million upfront and potential milestone payments of up to $730m to Neurimmune AG after entering ...

Article found on: www.cambridgeindependent.co.uk

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up